ClinicalTrials.gg

Program

vilobelimab

Also written as “IFX-1”, “Cohort A: vilobelimab” and “Vilobelimab”.

Its studies are mostly in Respiratory Distress Syndrome · Pyoderma Gangrenosum · Granulomatosis with Polyangiitis · Hidradenitis Suppurativa · Neoplasm Metastasis, led by 2 companies.

Furthest: phase 3, since Apr 1, 202013 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InflaRx110 open or runningphase 3since Apr 1, 2020Mar 18, 2011none ahead
PPD Development, LP22 open or runningphase 2since Nov 20, 2024Nov 20, 2024Jul 2028phase 2 · NCT06703073

Also a collaborator on its studies: edesa-biotech-inc, Hoffmann-La Roche, Merck, iqvia-pty-ltd and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 18, 2011First study: phase 1 study in SepsisNew to InflaRxInflaRx · NCT01319903 · 26 enrolled · Germany
  2. Sep 18, 2014Phase 2 study in SepsisInflaRx · NCT02246595 · 72 enrolled · Germany
  3. Jun 17, 2016Phase 2 study in Systemic Inflammatory Response SyndromeInflaRx · NCT02866825 · 116 enrolled · Germany
  4. Nov 29, 2016Phase 2 study in Hidradenitis SuppurativaInflaRx · NCT03001622 · 12 enrolled · Greece
  5. Feb 27, 2018Phase 2 study in Hidradenitis SuppurativaInflaRx · NCT03487276 · 179 enrolled · United States, Bulgaria, Canada and more
  6. Oct 16, 2018Phase 2 study in Granulomatosis with PolyangiitisInflaRx · NCT03712345 · 20 enrolled · United States, Canada
  7. Mar 8, 2019Phase 2 study in Granulomatosis with PolyangiitisInflaRx · NCT03895801 · 57 enrolled · Belgium, Czechia, France and more
  8. May 28, 2019Phase 2 study in Pyoderma GangrenosumInflaRx · NCT03971643 · 19 enrolled · United States, Canada, Poland
  9. Apr 1, 2020Phase 3 study in Severe COVID-19 PneumoniaInflaRx · NCT04333420 · 399 enrolled · Belgium, Brazil, France and more
  10. Mar 10, 2021Phase 2 study in Neoplasm MetastasisInflaRx · NCT04812535 · 30 enrolled · United States, Belgium, France and more
  11. Jun 29, 2023Phase 3 study in Pyoderma GangrenosumInflaRx · NCT05964413 · 54 enrolled · United States, Australia, Belgium and more
  12. Nov 20, 2024PPD Development, LP's first studies: 2 phase 2 studies in Respiratory Distress SyndromeNew to PPD Development, LPPPD Development, LP · NCT06703073, NCT06701682

Ahead

  1. Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06703073
  2. Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06701682

TargetBeta

C5 →read by rule
“A monoclonal antibody targeting the human complement factor C5a, ”NCIt, by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06703073Respiratory Distress Syndrome · United States2RecruitingPPD Development, LPJul 2028600
NCT06701682Respiratory Distress Syndrome · United States2RecruitingPPD Development, LPJul 2028200
NCT05964413Pyoderma Gangrenosum · United States, Australia, Belgium and more3TerminatedInflaRxJul 11, 202554
NCT04812535Neoplasm Metastasis · United States, Belgium, France and more2TerminatedInflaRxJun 4, 202430
NCT04333420Severe COVID-19 Pneumonia · Belgium, Brazil, France and more3CompletedInflaRxOct 31, 2021399
NCT03971643Pyoderma Gangrenosum · United States, Canada, Poland2CompletedInflaRxJan 3, 202219
NCT03895801Granulomatosis with Polyangiitis · Belgium, Czechia, France and more2CompletedInflaRxApr 14, 202157
NCT03712345Granulomatosis with Polyangiitis · United States, Canada2TerminatedInflaRxSep 10, 202020
NCT03487276Hidradenitis Suppurativa · United States, Bulgaria, Canada and more2CompletedInflaRxMay 27, 2019179
NCT03001622Hidradenitis Suppurativa · Greece2CompletedInflaRxJul 201712
NCT02866825Systemic Inflammatory Response Syndrome · Germany2CompletedInflaRxDec 2016116
NCT02246595Sepsis · Germany2CompletedInflaRxDec 201572
NCT01319903Sepsis · Germany1CompletedInflaRxOct 201126

How it is read

Names in the registry

  • “IFX-1”, 4 entries
  • “Cohort A: vilobelimab”, 2 entries
  • “vilobelimab”, 2 entries
  • “Vilobelimab”, 1 entry
  • “Vilobelimab + pembrolizumab combination therapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.